摘要
左西孟旦是新近研发的一种钙离子增敏剂,通过发挥独立于β-肾上腺素能的强心作用而治疗失代偿期心力衰竭(HF),在一些难治性HF治疗中疗效明显。现有证据表明左西孟旦在心源性休克,心脏围手术期和感染性休克等心血管危重症患者治疗中是安全有效的,能显著减少患者死亡率。但上述结论仍有待进一步随机对照研究(RCT)证实。
Levosimendan, a calcium sensitizer aimed at treating decompensated or refractory heart failure, exerts its positive inotropic effects independently of beta adrenergic receptor in cases of severe and intractable heart failure. Available evidences supports the concept that levosimendan is a safe and valid option in treating critically ill cardiovascular patients. Additional data from well-designed randomized prospective controlled trials in critically ill patients is warranted to appreciate the therapeutic role or roles for levosimendan in critically ill cardiovascular pateints.
出处
《心脏杂志》
CAS
2018年第1期113-116,共4页
Chinese Heart Journal
基金
军队保健专项课题资助(14BJZ25)
关键词
左西孟旦
心力衰竭
心源性休克
心肌梗死
感染性休克
levosimendan
congestive heart failure
cardiogenic shock
myocardial infarction
septic shock
